Advanced Asset Management Advisors Inc Cuts Stake in Johnson & Johnson (NYSE:JNJ)

Advanced Asset Management Advisors Inc lowered its holdings in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 0.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 48,987 shares of the company’s stock after selling 246 shares during the quarter. Johnson & Johnson makes up 1.9% of Advanced Asset Management Advisors Inc’s portfolio, making the stock its 17th biggest holding. Advanced Asset Management Advisors Inc’s holdings in Johnson & Johnson were worth $8,682,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in JNJ. BlackRock Inc. lifted its stake in shares of Johnson & Johnson by 2.6% in the 4th quarter. BlackRock Inc. now owns 200,021,352 shares of the company’s stock valued at $34,217,654,000 after purchasing an additional 4,982,885 shares during the last quarter. State Street Corp lifted its stake in shares of Johnson & Johnson by 1.8% in the 4th quarter. State Street Corp now owns 144,677,639 shares of the company’s stock valued at $24,750,004,000 after purchasing an additional 2,492,359 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Johnson & Johnson by 2.5% in the 4th quarter. Geode Capital Management LLC now owns 44,405,610 shares of the company’s stock valued at $7,576,867,000 after purchasing an additional 1,084,834 shares during the last quarter. Norges Bank bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at approximately $4,172,929,000. Finally, Legal & General Group Plc lifted its stake in shares of Johnson & Johnson by 5.8% in the 4th quarter. Legal & General Group Plc now owns 17,420,146 shares of the company’s stock valued at $2,980,062,000 after purchasing an additional 948,306 shares during the last quarter. 68.78% of the stock is owned by institutional investors.

Johnson & Johnson Trading Up 1.0 %

JNJ opened at $174.59 on Thursday. The stock’s fifty day moving average is $175.57 and its two-hundred day moving average is $174.49. The company has a market capitalization of $459.42 billion, a P/E ratio of 25.41, a PEG ratio of 3.31 and a beta of 0.59. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69. The company has a quick ratio of 1.14, a current ratio of 1.42 and a debt-to-equity ratio of 0.37.

Johnson & Johnson (NYSE:JNJGet Rating) last released its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The company had revenue of $24.02 billion for the quarter, compared to the consensus estimate of $23.85 billion. During the same period last year, the business posted $2.48 EPS. Johnson & Johnson’s quarterly revenue was up 3.0% on a year-over-year basis. Analysts forecast that Johnson & Johnson will post 10.05 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd will be issued a $1.13 dividend. The ex-dividend date of this dividend is Monday, August 22nd. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.59%. Johnson & Johnson’s dividend payout ratio is presently 65.79%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on JNJ shares. UBS Group lowered their price objective on Johnson & Johnson from $185.00 to $180.00 in a research note on Thursday, July 21st. SVB Leerink reduced their price target on Johnson & Johnson from $200.00 to $194.00 in a report on Wednesday, July 20th. Morgan Stanley increased their price target on Johnson & Johnson from $173.00 to $174.00 and gave the stock an “equal weight” rating in a report on Friday, July 8th. Citigroup reduced their price target on Johnson & Johnson from $205.00 to $201.00 in a report on Wednesday, July 20th. Finally, Daiwa Capital Markets assumed coverage on Johnson & Johnson in a report on Wednesday, June 22nd. They issued an “outperform” rating on the stock. Four analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $189.89.

Insider Activity

In other news, CAO Robert J. Decker sold 8,462 shares of Johnson & Johnson stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the transaction, the chief accounting officer now directly owns 15,473 shares in the company, valued at approximately $2,785,140. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CAO Robert J. Decker sold 8,462 shares of Johnson & Johnson stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the transaction, the chief accounting officer now directly owns 15,473 shares in the company, valued at approximately $2,785,140. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction on Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the transaction, the executive vice president now owns 71,311 shares in the company, valued at $12,336,803. The disclosure for this sale can be found here. Company insiders own 0.35% of the company’s stock.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Want More Great Investing Ideas?

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.